Aldeyra announces positive results from Phase 2b clinical trial

Date: 2018-10-01   Author: Paroma Bhattacharya  Category: #technology

Aldeyra announces positive results from Phase 2b clinical trial

Aldeyra Therapeutics, Inc., a biotechnology company engaged in research and development of medicines related to immune-mediated diseases, has recently announced to have received positive results from its topical ocular reproxalap’s Phase 2b clinical trial, conducted on patients with dry eye disease.

As per an official press release, John Sheppard, M.D., Professor of Ophthalmology at Eastern Virginia Medical School, said that the recently announced positive results confirm the potential of reproxalap, a drug with a novel mechanism of action, as a promising therapeutic agent for treating dry eye disease, which remains a persistently challenging medical condition for many patients worldwide.

Sources suggest that the randomized, parallel-group, vehicle-controlled, double-masked, multi-center, Phase 2b clinical trial investigated 0.1% and 0.25% reproxalap concentrations activity relative to vehicle, along with observed clear dose response. Despite being consistent with prior clinical trials, topical ocular reproxalap was well tolerated, while adverse events were speculated to be generally mild.

Nearly three hundred patients suffering from dry eye disease were equally treated with 0.1%, 0.25%, or vehicle dosages for 12 weeks. The primary objective of the trial was to evaluate the safety and efficiency of reproxalap for the treatment of the symptoms and signs of dry eye disease, in order to confirm endpoint selection, to select appropriate drug concentration, and to determine sample size for a pivotal Phase 3 clinical program.

Todd C. Brady, CEO of Aldeyra, was quoted saying that with the successful Phase 2b results the company is looking forward to initiating a Phase 3 program in dry eye disease in 2019, soon after following discussion with regulatory authorities.

The addition of treatment of dry eye disease to Aldeyra’s clinical portfolio, including Phase 3 clinical trials in noninfectious anterior uveitis and allergic conjunctivitis, will highlight the potential of reproxalap as a novel ophthalmic therapy, said Brady.



About Author


Paroma Bhattacharya twitter

...

Read More

More News from Paroma


Post Recommendents

UK Commercial Boiler Market Presents an Overall Analysis, Share, Trends and Forecast to 2026

Author: Rahul Varpe

DEC Research recently introduced report on UK Commercial Boiler Market Report is an in-depth study providing complete analysis of the industry for the period 2018 to 2023. It provides complete overview of Global industry considering all the major ...


Early Production Facility Market Expected to Witness the Highest Growth 2026

Author: Rahul Varpe

DEC Research presents the Early Production Facility Market provides a detailed overview of major drivers, restraints, challenges, opportunities, current industry trends and strategies impacting the global market along with estimates and forecast o...


Low Voltage Switchgear Market Overview with Detailed Analysis, Competitive landscape, Forecast to 2025

Author: Rahul Varpe

DEC Research added research on Low Voltage Switchgear Market is a detailed analysis of this business space inclusive of the trends, competitive landscape, and the market size. Encompassing one or more parameters among product analysis, application...